Advanced Heart Failure Market

Market Overview:

The 7 major advanced heart failure markets reached a value of USD 6.5 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 27.6 Billion by 2035, exhibiting a growth rate (CAGR) of 14.05% during 2025-2035.

The advanced heart failure market has been comprehensively analyzed in IMARC's new report titled "Advanced Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Advanced heart failure refers to a critical stage of cardiac disease where the heart's ability to pump blood efficiently becomes severely compromised. This condition typically arises as a progression from earlier stages of heart failure and is characterized by a significant reduction in the heart's pumping capacity. Common symptoms of the ailment encompass breathlessness, even during rest, extreme fatigue, fluid retention leading to swelling in the legs and ankles (edema), and difficulty performing routin e activities due to decreased exercise tolerance. Patients might also experience frequent hospitalizations due to worsening indications and increased vulnerability to complications. Diagnosing advanced heart failure involves a comprehensive evaluation by healthcare professionals. This usually includes a thorough medical history review, a physical investigation to assess the severity of indications and signs of fluid retention, and often the use of imaging techniques like echocardiography to detect cardiac structure and function. Blood workups are also recommended to determine markers of heart stress and damage.

The escalating cases of various underlying causes, such as cardiomyopathy, coronary artery disease, and long-standing hypertension that can induce functional and structural changes in the myocardium, are primarily driving the advanced heart failure market. In addition to this, the inflating utilization of tailored cardiac rehabilitation programs, which are recognized for their efficacy in enhancing cardiac function, optimizing exercise tolerance, and improving the overall quality of life, is also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological approaches like angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors, on account of their several advantages, including halting disease progression, reducing the strain on the heart, and lessening symptoms of the illness, is further bolstering the market growth. Apart from this, the rising usage of gene-editing technologies, since they aim to rectify genetic anomalies responsible for cardiac disorders, thereby presenting an exciting avenue for potential therapeutic breakthroughs, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine, involving techniques such as tissue engineering and stem cell therapy to repair damaged cardiac tissue and reverse the course of the ailment, is expected to drive the advanced heart failure market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the advanced heart failure market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced heart failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced heart failure market in any manner.

Recent Developments:

• In November 2024, Eli Lilly and Company unveiled findings from the SUMMIT Phase 3 trial, highlighting that tirzepatide significantly reduced the risk of worsening heart failure events in adults living with heart failure with preserved ejection fraction (HFpEF) and obesity. The treatment also led to substantial improvements in heart failure-related symptoms and physical limitations. These groundbreaking results were simultaneously published in The New England Journal of Medicine and presented at the American Heart Association (AHA) Scientific Sessions 2024.

Drugs:

Farxiga (Dapagliflozin) is an SGLT2 inhibitor developed by AstraZeneca, primarily used to treat advanced heart failure with reduced ejection fraction (HFrEF). It works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, leading to reduced glucose reabsorption and increased glucose excretion. This helps to lower blood sugar and reduce the strain on the heart, improving cardiovascular outcomes. Additionally, Farxiga has demonstrated benefits in reducing hospitalization for heart failure and improving survival in patients with advanced heart failure.

Entresto (Sacubitril and Valsartan) is an approved medication for treating heart failure with reduced ejection fraction (HFrEF). It combines Sacubitril, which inhibits neprilysin to increase beneficial natriuretic peptides, and Valsartan, an angiotensin II receptor blocker that helps relax blood vessels. This dual action helps reduce fluid buildup, lower blood pressure, and improve heart function, leading to better survival rates and fewer hospitalizations in patients with advanced heart failure.

Corlanor (Ivabradine) is an approved medication used to treat advanced heart failure with reduced ejection fraction (HFrEF). It works by selectively inhibiting the "funny" (If) current in the sinoatrial node, which slows the heart rate without affecting blood pressure. This helps reduce the heart's workload, improve cardiac function, and reduce the risk of hospitalization due to heart failure symptoms. Corlanor is typically used in combination with other heart failure treatments.

Inpefa (Sotagliflozin), a dual SGLT1 and SGLT2 inhibitor, is designed to treat advanced heart failure. It works by regulating glucose levels and reducing fluid retention, helping to ease symptoms and decrease cardiovascular risks. This innovative treatment provides a new option for improving outcomes in heart failure patients.

Tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company, is being explored as a potential therapy for advanced heart failure. By harnessing its metabolic and anti-inflammatory properties, the drug shows promise in addressing heart failure, particularly in patients with HFpEF and obesity. Initial trials have delivered positive results, demonstrating improved symptoms and outcomes. As research continues to evaluate its long-term safety and efficacy, tirzepatide represents a novel approach to treating advanced heart failure.
 

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the advanced heart failure market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the advanced heart failure market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current advanced heart failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the advanced heart failure market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the advanced heart failure market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the advanced heart failure market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of advanced heart failure across the seven major markets?
• What is the number of prevalent cases (2019-2035) of advanced heart failure by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of advanced heart failure by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with advanced heart failure across the seven major markets?
• What is the size of the advanced heart failure patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of advanced heart failure?
• What will be the growth rate of patients across the seven major markets?
   

Advanced Heart Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for advanced heart failure drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced heart failure market?
• What are the key regulatory events related to the advanced heart failure market?
• What is the structure of clinical trial landscape by status related to the advanced heart failure market?
• What is the structure of clinical trial landscape by phase related to the advanced heart failure market?
• What is the structure of clinical trial landscape by route of administration related to the advanced heart failure market?